JP2005506061A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506061A5
JP2005506061A5 JP2003514002A JP2003514002A JP2005506061A5 JP 2005506061 A5 JP2005506061 A5 JP 2005506061A5 JP 2003514002 A JP2003514002 A JP 2003514002A JP 2003514002 A JP2003514002 A JP 2003514002A JP 2005506061 A5 JP2005506061 A5 JP 2005506061A5
Authority
JP
Japan
Prior art keywords
peptide
pharmaceutical composition
composition according
disease
gland
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003514002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506061A (ja
JP4587667B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2002/001106 external-priority patent/WO2003008444A2/en
Publication of JP2005506061A publication Critical patent/JP2005506061A/ja
Publication of JP2005506061A5 publication Critical patent/JP2005506061A5/ja
Application granted granted Critical
Publication of JP4587667B2 publication Critical patent/JP4587667B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003514002A 2001-07-19 2002-07-19 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド Expired - Lifetime JP4587667B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30616101P 2001-07-19 2001-07-19
US30615001P 2001-07-19 2001-07-19
US33147701P 2001-11-16 2001-11-16
PCT/CA2002/001106 WO2003008444A2 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Publications (3)

Publication Number Publication Date
JP2005506061A JP2005506061A (ja) 2005-03-03
JP2005506061A5 true JP2005506061A5 (cg-RX-API-DMAC7.html) 2006-01-05
JP4587667B2 JP4587667B2 (ja) 2010-11-24

Family

ID=27405149

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003514001A Pending JP2005507647A (ja) 2001-07-19 2002-07-19 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2003514002A Expired - Lifetime JP4587667B2 (ja) 2001-07-19 2002-07-19 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
JP2011035954A Pending JP2011152133A (ja) 2001-07-19 2011-02-22 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2013078281A Expired - Lifetime JP5622885B2 (ja) 2001-07-19 2013-04-04 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003514001A Pending JP2005507647A (ja) 2001-07-19 2002-07-19 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011035954A Pending JP2011152133A (ja) 2001-07-19 2011-02-22 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2013078281A Expired - Lifetime JP5622885B2 (ja) 2001-07-19 2013-04-04 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Country Status (22)

Country Link
US (2) US7192929B2 (cg-RX-API-DMAC7.html)
EP (2) EP1417227B1 (cg-RX-API-DMAC7.html)
JP (4) JP2005507647A (cg-RX-API-DMAC7.html)
KR (2) KR100966232B1 (cg-RX-API-DMAC7.html)
CN (1) CN100475843C (cg-RX-API-DMAC7.html)
AT (1) ATE353914T1 (cg-RX-API-DMAC7.html)
AU (2) AU2002319049B2 (cg-RX-API-DMAC7.html)
BR (2) BR0211199A (cg-RX-API-DMAC7.html)
CA (2) CA2453967C (cg-RX-API-DMAC7.html)
CY (1) CY1108009T1 (cg-RX-API-DMAC7.html)
DE (2) DE60217507T2 (cg-RX-API-DMAC7.html)
DK (1) DK1417228T3 (cg-RX-API-DMAC7.html)
EA (1) EA006603B1 (cg-RX-API-DMAC7.html)
ES (2) ES2281529T3 (cg-RX-API-DMAC7.html)
IL (2) IL159903A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000561A (cg-RX-API-DMAC7.html)
NO (1) NO333999B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ531114A (cg-RX-API-DMAC7.html)
PL (1) PL207588B1 (cg-RX-API-DMAC7.html)
PT (1) PT1417228E (cg-RX-API-DMAC7.html)
WO (2) WO2003008444A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200401320B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
DE60222745T2 (de) * 2001-03-08 2008-07-10 Nymox Pharmaceutical Corp., St. Laurent Verwendung von neurofilamentproteinen zur behandlung von tumoren
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
DE60217507T2 (de) * 2001-07-19 2007-11-15 Nymox Corp., Saint-Laurent Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2003048188A2 (en) * 2001-12-04 2003-06-12 Millennium Pharmaceuticals, Inc. 15603, a human ion channel family member
EP1646648A2 (en) * 2003-07-15 2006-04-19 Genova Ltd. Secreted polypeptide species reduced in cardiovascular disorders
CN1822853A (zh) * 2003-07-15 2006-08-23 加拿大国家研究委员会 用于治疗特征在于过度增殖皮肤细胞的疾病的人类甲状旁腺激素环状类似物
CA2555306A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
US20060173490A1 (en) 2005-02-01 2006-08-03 Boston Scientific Scimed, Inc. Filter system and method
PL1994152T3 (pl) 2006-02-28 2013-05-31 Nymox Corp Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek
EA200801942A1 (ru) * 2006-03-10 2009-02-27 Наймокс Корпорейшн Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
TR201802233T4 (tr) * 2007-10-25 2018-03-21 Toray Industries İmmün cevap indükleyiciler.
JP5572938B2 (ja) * 2007-10-25 2014-08-20 東レ株式会社 免疫誘導剤
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
KR20110015571A (ko) * 2008-04-24 2011-02-16 더리무넥 파마큐티컬스, 아이엔씨. 펩티딜 디아실글리세라이드
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
US20160215031A1 (en) * 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US20160361380A1 (en) * 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) * 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) * 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
WO2019195851A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
EA202191201A1 (ru) 2018-12-03 2022-01-26 Эдженсис, Инк. Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378924B1 (en) * 1988-12-21 1996-11-13 The General Hospital Corporation Detection of neurological disease or dysfunction
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
AU749348B2 (en) * 1997-02-26 2002-06-27 General Hospital Corporation, The Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
AU765110B2 (en) * 1998-06-26 2003-09-11 Georgetown University Medical Center Compositions and methods for inducing cell death
AU2185199A (en) * 1998-09-30 2000-04-17 Yoko Aida Apoptosis inducers
EP1135494A2 (en) * 1998-12-11 2001-09-26 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
DE60003632T2 (de) * 1999-01-11 2004-04-15 Leadd B.V. Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten
AU3517000A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. 50 human secreted proteins
JP2002543764A (ja) * 1999-03-19 2002-12-24 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 46個のヒト分泌タンパク質
JP2002539842A (ja) 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 45個のヒト分泌タンパク質
EP1220947A2 (en) * 1999-03-26 2002-07-10 Human Genome Sciences, Inc. 50 human secreted proteins
EP1171462A2 (en) 1999-03-26 2002-01-16 Human Genome Sciences, Inc. 49 human secreted proteins
CN1300779A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽-人神经元线蛋白17和编码这种多肽的多核苷酸
CN1300783A (zh) 1999-12-23 2001-06-27 上海生元基因开发有限公司 新的人神经元线蛋白及其编码序列
WO2002000718A2 (en) * 2000-06-26 2002-01-03 Millennium Pharmaceuticals, Inc. A human calcium channel protein and uses thereof
CN1352145A (zh) * 2000-11-10 2002-06-05 上海博德基因开发有限公司 一种新的多肽——锌指蛋白14.08和编码这种多肽的多核苷酸
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
BR0209990A (pt) * 2001-05-25 2004-06-29 Nymox Corp Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE60217507T2 (de) * 2001-07-19 2007-11-15 Nymox Corp., Saint-Laurent Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern

Similar Documents

Publication Publication Date Title
JP2005521383A5 (cg-RX-API-DMAC7.html)
JP2005507647A5 (cg-RX-API-DMAC7.html)
JP2004534533A5 (cg-RX-API-DMAC7.html)
ES2255248T3 (es) Derivados de antigenos asociados a tumor de la familia mage, y secuencias de acidos nucleicos que los codifican, usados para la preparacion de proteinas de fusion y de composiciones para vacunas.
JP2004529908A5 (cg-RX-API-DMAC7.html)
CN105705522B (zh) 针对低免疫原性蛋白的表位疫苗及其制法和用途
JP2003531632A (ja) グルカゴンアンタゴニスト
US20080057064A1 (en) Erbb3 Based Methods and Compositions for Treating Neoplasms
EP2281040B1 (en) Lyophilized dna formulations for enhanced expression of plasmid dna
JP2021518745A5 (ja) アクチビンiib型受容体変異体および同変異体を含む医薬組成物
JPH06502771A (ja) 筋細胞内での発現のためのウイルス性組換え型ベクター
JP2002524078A (ja) 子宮頸がんの治療
US20210403948A1 (en) Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof
JP2021515572A5 (cg-RX-API-DMAC7.html)
JP2022505877A5 (cg-RX-API-DMAC7.html)
US6989374B1 (en) Gene therapy for cardiomyopathy
JP2004528266A (ja) 薬物送達用組成物
JP2024513559A5 (cg-RX-API-DMAC7.html)
JP2006517104A (ja) トランスポゾンに基づく標的化システム
JP2003530088A5 (cg-RX-API-DMAC7.html)
PT98695A (pt) Gene codificador do factor neurotrofico de ligacao a heparina
CA2378925A1 (en) Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
RU2013113639A (ru) Иммунотерапевтический способ лечения рака простаты
JP2002505847A (ja) Rhipicephalusappendiculatus由来の組織セメントタンパク質
CN100435848C (zh) 提高饲料效率和家畜生长速度的基因处理